These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 1712649

  • 1. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H.
    Blood; 1991 Jul 15; 78(2):401-9. PubMed ID: 1712649
    [Abstract] [Full Text] [Related]

  • 2. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H.
    J Clin Invest; 1989 Aug 15; 84(2):647-55. PubMed ID: 2503541
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.
    Kunitada S, FitzGerald GA, Fitzgerald DJ.
    Blood; 1992 Mar 15; 79(6):1420-7. PubMed ID: 1547340
    [Abstract] [Full Text] [Related]

  • 4. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 5. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
    Pöllänen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW.
    Proc Natl Acad Sci U S A; 1990 Mar 20; 87(6):2230-4. PubMed ID: 2138329
    [Abstract] [Full Text] [Related]

  • 6. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies.
    Rondeau E, Mougenot B, Lacave R, Peraldi MN, Kruithof EK, Sraer JD.
    Clin Nephrol; 1990 Feb 20; 33(2):55-60. PubMed ID: 2107050
    [Abstract] [Full Text] [Related]

  • 7. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R, Black J, Gurewich V.
    J Clin Invest; 1988 Mar 20; 81(3):853-9. PubMed ID: 2963831
    [Abstract] [Full Text] [Related]

  • 8. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D.
    J Biol Chem; 1988 Dec 15; 263(35):19083-91. PubMed ID: 3143723
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolysis: the key to new pathogenetic mechanisms.
    Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A.
    Curr Med Chem; 2008 Dec 15; 15(9):923-9. PubMed ID: 18473800
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V, Pannell R.
    Thromb Res; 1986 Oct 15; 44(2):217-28. PubMed ID: 3097872
    [Abstract] [Full Text] [Related]

  • 11. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
    Keijer J, Ehrlich HJ, Linders M, Preissner KT, Pannekoek H.
    J Biol Chem; 1991 Jun 05; 266(16):10700-7. PubMed ID: 1709939
    [Abstract] [Full Text] [Related]

  • 12. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D.
    Blood; 1990 May 01; 75(9):1794-800. PubMed ID: 1691934
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
    Reilly CF, Hutzelmann JE.
    J Biol Chem; 1992 Aug 25; 267(24):17128-35. PubMed ID: 1512250
    [Abstract] [Full Text] [Related]

  • 14. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
    Nielsen JD, Gram J, Fabrin K, Holm-Nielsen A, Jespersen J.
    Br J Urol; 1997 Jul 25; 80(1):105-10. PubMed ID: 9240188
    [Abstract] [Full Text] [Related]

  • 15. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
    Dong Q, Zhou MH, Subbarao V, Ts'ao CH.
    Br J Exp Pathol; 1988 Oct 25; 69(5):685-95. PubMed ID: 3143395
    [Abstract] [Full Text] [Related]

  • 16. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro.
    Ramsby ML, Kreutzer DL.
    Invest Ophthalmol Vis Sci; 1993 Oct 25; 34(11):3207-19. PubMed ID: 7691778
    [Abstract] [Full Text] [Related]

  • 17. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
    Nguyen G, Horellou MH, Kruithof EK, Conard J, Samama MM.
    Blood; 1988 Aug 25; 72(2):601-5. PubMed ID: 3135860
    [Abstract] [Full Text] [Related]

  • 18. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
    Stringer HA, Pannekoek H.
    J Biol Chem; 1995 May 12; 270(19):11205-8. PubMed ID: 7744752
    [Abstract] [Full Text] [Related]

  • 19. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA, Owensby DA, Sobel BE, Schwartz AL.
    J Biol Chem; 1989 May 05; 264(13):7228-35. PubMed ID: 2540181
    [Abstract] [Full Text] [Related]

  • 20. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
    Meissauer A, Kramer MD, Hofmann M, Erkell LJ, Jacob E, Schirrmacher V, Brunner G.
    Exp Cell Res; 1991 Feb 05; 192(2):453-9. PubMed ID: 1899072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.